Similar Items: REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
- Real-World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review
- Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice
- Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
- Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area
- Corrigendum to “Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”